Sorafenib for Patients With Extensive Keloids

Summary

Treatment of keloid disorder is an area of unmet medical need. Current treatments for keloid partially address small and localized keloids, yet there are no wholly satisfactory or effective treatments for patients with extensive keloids. Such patients may benefit from effective systemic treatments. Sorafenib has the potential to regulate the three known dysregulated biological pathways in keloid tissue.

Timeline

Start

2013-03

Primary completion

2013-03

Completion

2013-03

Outcome

Outcome not reported

Stopped: “IND application was not approved by the US FDA - Project was never started”

Drugs

Indications